Skip to content

A Phase I, Single-Centre, Double-Blind, Randomized, Placebo-Controlled Clinical Trial To Determine Urinary Xylose Cut-Off Point For The Diagnosis Of Hypolactasia, After A Single Dose Of Gaxilose in Children Between 5 – 11 Years Of Age.

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-504232-18-00
Acronym
VPH-GXL-2022-511
Enrollment
18
Registered
2023-06-16
Start date
2023-06-22
Completion date
2023-06-30
Last updated
2023-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypolactasia

Brief summary

PK analysis for urinary xylose excretion will be based on the following parameters: maximum urinary excretion rate detected at 0-3, 3-4 and 4-5h; its mean time during the corresponding interval (Tmax) and total xylose excreted (Ae0-5). All urine samples will be analyzed at a laboratory located in Hospital Universitario de Getafe

Detailed description

The incidence of adverse events (AEs), as well as relevant and abnormal changes from baseline in laboratory test results, and changes to vital signs in the treatment arm compared to the control arm.

Interventions

Sponsors

Venter Pharma S.L.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
PK analysis for urinary xylose excretion will be based on the following parameters: maximum urinary excretion rate detected at 0-3, 3-4 and 4-5h; its mean time during the corresponding interval (Tmax) and total xylose excreted (Ae0-5). All urine samples will be analyzed at a laboratory located in Hospital Universitario de Getafe

Secondary

MeasureTime frame
The incidence of adverse events (AEs), as well as relevant and abnormal changes from baseline in laboratory test results, and changes to vital signs in the treatment arm compared to the control arm.

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026